Artemether
FDA-approved product (tablet, oral).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBL- WHO therapeutic group
- Artemisinin and derivatives, plain
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BE02; WHO ATC P01BE05
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Artemether, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA39.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae16.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis22.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Artemether with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pipecuronium BromideExisting use: Other quaternary ammonium compounds42.9% AI-predicted activityagainst K. pneumoniae5 registered studies
- Fosaprepitant DimeglumineExisting use: Cancer, Chemotherapy-induced nausea and vomiting, Nausea and 3 more42.9% AI-predicted activityagainst K. pneumoniae21 registered studies
- CabergolineExisting use: Hypothalamic neoplasm, Parkinson disease42.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Fondaparinux SodiumExisting use: Deep vein thrombosis, Intermediate coronary syndrome, Myocardial infarction and 3 more42.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder42.6% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Vecuronium BromideExisting use: Other quaternary ammonium compounds42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease42.0% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- Lumateperone TosylateExisting use: Psychosis, Schizophrenia41.9% AI-predicted activityagainst K. pneumoniae6 registered studies
- RepotrectinibExisting use: Cancer, Neoplasm41.8% AI-predicted activityagainst K. pneumoniae17 registered studies
- MoxidectinExisting use: Helminthiasis, Onchocerciasis41.7% AI-predicted activityagainst K. pneumoniae25 registered studies
- PralsetinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 1 more41.5% AI-predicted activityagainst K. pneumoniae19 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.
NCT00386763 · start 2006-08
Registered record
- Registry ID
- NCT00386763
- Conditions
- Malaria; Falciparum
- Interventions
- Artemether-lumefantrine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-08
- Completion
- 2007-03
- Enrolment
- 890
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMalaria; FalciparumInterventionArtemether-lumefantrinePhasePhase 3Registry statusCompletedATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria
NCT00316329 · start 2006-03
Registered record
- Registry ID
- NCT00316329
- Conditions
- Malaria
- Interventions
- Artesunate + Amodiaquine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-03
- Completion
- Not recorded
- Enrolment
- 1,032
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMalariaInterventionArtesunate + AmodiaquinePhasePhase 3Registry statusCompletedAmodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children
NCT00406146 · start 2004-10
Registered record
- Registry ID
- NCT00406146
- Conditions
- Uncomplicated Malaria
- Interventions
- amodiaquine+artesunate/artemether-lumefantrine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2004-10
- Completion
- 2006-12
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUncomplicated MalariaInterventionamodiaquine+artesunate/artemether-lumefantrinePhasePhase 3Registry statusUnknownLapdap and Coartemether for Uncomplicated Malaria
NCT00118794 · start 2004-09
Registered record
- Registry ID
- NCT00118794
- Conditions
- Malaria
- Interventions
- Chlorproguanil-dapsone (Lapdap); Lumefantrine-artemether (Coartemether )
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-09
- Completion
- 2005-06
- Enrolment
- 1,200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMalariaInterventionChlorproguanil-dapsone (Lapdap); Lumefantrine-artemether (Coartemether )PhasePhase 3Registry statusCompletedComparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status
NCT00304980 · start 2003-03
Registered record
- Registry ID
- NCT00304980
- Conditions
- Plasmodium Falciparum Malaria
- Interventions
- ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2003-03
- Completion
- 2005-04
- Enrolment
- 3,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPlasmodium Falciparum MalariaInterventionARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINEPhaseNot applicableRegistry statusTerminated